Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Expenses: 2020-2024

Historic Operating Expenses for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $236.7 million.

  • Xeris Biopharma Holdings' Operating Expenses rose 0.73% to $67.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.3 million, marking a year-over-year increase of 10.24%. This contributed to the annual value of $236.7 million for FY2024, which is 13.85% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Operating Expenses of $236.7 million as of FY2024, which was up 13.85% from $207.9 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' Operating Expenses ranged from a high of $236.7 million in FY2024 and a low of $104.0 million during FY2020.
  • For the 3-year period, Xeris Biopharma Holdings' Operating Expenses averaged around $212.3 million, with its median value being $207.9 million (2023).
  • Data for Xeris Biopharma Holdings' Operating Expenses shows a peak YoY surged of 58.44% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Xeris Biopharma Holdings' Operating Expenses stood at $104.0 million in 2020, then surged by 58.44% to $164.7 million in 2021, then rose by 16.66% to $192.2 million in 2022, then grew by 8.19% to $207.9 million in 2023, then rose by 13.85% to $236.7 million in 2024.